NY-UPFLEX
25.5.2022 15:02:13 CEST | Business Wire | Press release
Upflex —the premier global provider of hybrid workspace solutions—announced the closing of its $30 million Series A round. The raise was led by WeWork with participation from notable strategic investors Newmark and Cushman & Wakefield as well as returning investor Ecosystem Integrity Fund , and top venture funds including GPO Fund , Coelius Capital , Industry Ventures , Inertia Ventures , Perennial Private Investments , and Silicon Valley Bank . This brings Upflex’s total funds raised to-date to $34.1 million.
Upflex entered into a strategic and exclusive partnership with WeWork in February 2022 which increased Upflex’s global network to over 6,000 bookable locations. As the sole aggregator of WeWork inventory, Upflex and WeWork clients now benefit from enhanced optionality in workspaces as they aim to adopt hybrid work strategies.
“We’re excited and humbled to partner with global leaders in commercial real estate and top proptech investors who bring the market expertise and the financial backing that is needed to further our growth,” said Christophe Garnier , CEO & Co-Founder of Upflex. “We plan to leverage the funds to expand our market leading technology and team as we continue to cement ourselves as the backbone of the flex industry, setting the standard for what today’s employers and employees seek in the workplace.”
Founded in 2018, Upflex will utilize this capital infusion to further accelerate its core mission of creating a multi-faceted technology standard that connects occupiers, brokerage firms and flex space partners with the solutions that the flex industry needs to meet the demand of the hybrid generation. Upflex’s data-driven solutions help reduce overhead while simultaneously increasing sustainability, satisfaction as well as scalability for companies of all sizes, from start-ups through global enterprises. The fast growth prop tech startup plans to expand its software offering, recruit top talent as well as expand its comprehensive network to 30,000 bookable workspaces by 2025.
“WeWork has always been at the forefront of workplace innovation and we are constantly looking for best-in-class partners to enhance the solutions we provide to companies of all sizes around the world,” said Sandeep Mathrani , CEO of WeWork. “We’re confident that our exclusive partnership with Upflex provides an advantage in our ability to support a more flexible, hybrid world of work.”
For flexible space partners, Upflex creates enhanced exposure for their portfolio of assets, while enabling them to manage their inventory without added incremental capital investments. For employees, it enables office location and desk booking flexibility while empowering employers to expand their definition of workspace, bringing their owned and leased real estate into the same centralized, easy-to-use booking ecosystem with a worldwide network of thousands of workspaces on demand. Managers have access to real-time usage data and trends over time, enabling them to create customized, long-term hybrid solutions optimized to their business objectives, employee happiness and sustainability goals. Upflex’s technology and space network have been tapped to power portfolio management tools and client offerings by some of the world’s leading brokerages.
Upflex—which continues to deliver an unparalleled employee choice and experience, robust data backbone, in-depth employer workspace controls and access to the best quality marketplace of flex spaces—currently boasts on-demand access to more than 6,000 bookable locations spanning 80 countries, 900 cities and growing. In addition to its exclusive partnership with WeWork, Upflex has more than 700 other flex operator partners.
About Upflex: Upflex is a fast-growing, global proptech company offering a suite of SaaS solutions for the hybrid workplace. Upflex’s all-in-one technology stands to become the flex industry standard, connecting occupiers, brokerages and flex space providers in one seamless ecosystem that champions flexibility and choice, and makes distributed work simpler, more cost-efficient, more sustainable, more scalable, and more secure. A technology-driven company, Upflex is built on the belief that the key to a better world of work lies in data. Their platforms provide users with rich, actionable workspace usage data to drive smarter workspace decisions, and greater efficiency overall, for companies, for the workforce, and for the planet.
About WeWork: WeWork (NYSE: WE) was founded in 2010 with the vision to create environments where people and companies come together and do their best work. Since then, we’ve become one of the leading global flexible space providers committed to delivering technology-driven turnkey solutions, flexible spaces, and community experiences.
For more information about WeWork, please visit us at WeWork.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005769/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom